U.S. markets open in 2 hours 39 minutes

Ekso Bionics Holdings, Inc. (EKSO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.2500-0.1600 (-3.63%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close4.4100
Open4.3300
Bid4.0600 x 1200
Ask0.0000 x 800
Day's Range4.1100 - 4.4700
52 Week Range2.2500 - 11.7750
Volume267,824
Avg. Volume2,939,162
Market Cap35.153M
Beta (5Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-3.0480
Earnings DateJul 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Ekso Bionics to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on September 16, 2020

    RICHMOND, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that Jack Glenn, Chief Financial Officer of Ekso Bionics, will present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference at 11:30 am ET / 8:30 am PT on Wednesday, September 16, 2020. A live and archived webcast of the presentation will be available on the investor section of the company’s website at: www.eksobionics.com.About Ekso Bionics®  Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com or follow @EksoBionics on Twitter.Media Contact: Carrie Yamond Mas 917-371-2320 cmas@eksobionics.comInvestor Contact: David Carey 212-867-1768 investors@eksobionics.com

  • How Does Ekso Bionics Holdings' (NASDAQ:EKSO) CEO Salary Compare to Peers?
    Simply Wall St.

    How Does Ekso Bionics Holdings' (NASDAQ:EKSO) CEO Salary Compare to Peers?

    Jack Peurach has been the CEO of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) since 2018, and this article will examine...

  • Ekso Bionics® Unveils its Latest Assistive Exoskeleton Innovation for Industrial Use
    GlobeNewswire

    Ekso Bionics® Unveils its Latest Assistive Exoskeleton Innovation for Industrial Use

    EVO Upper Body Exoskeleton by Ekso Bionics Ekso Bionics, an industry leader in exoskeleton technology, unveiled EVO, an endurance-boosting assistive upper body exoskeleton that alleviates the burden of repetitive work. Building on the Company’s trailblazing EksoVest technology, EVO’s innovative design is the next step in the evolution of industrial exoskeletons. Ekso Bionics' EVO Upper Body Exoskeleton Ekso Bionics reimagined its weight-assist exoskeleton technology based on in-the-field customer feedback from leaders in global manufacturing and construction. Called EVO, this innovative upper body exoskeleton features a new patented low profile and is light, flexible, and cool and comfortable to wear for all-day use, while also maintaining the ruggedness and durability that Ekso is known for. The Next Step in the Evolution of Industrial Exoskeletons Ekso Bionics, an industry leader in exoskeleton technology, unveiled EVO, an endurance-boosting assistive upper body exoskeleton that alleviates the burden of repetitive work. Building on the Company’s trailblazing EksoVest technology, EVO’s innovative design is the next step in the evolution of industrial exoskeletons. RICHMOND, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today unveiled EVOTM, an endurance-boosting assistive upper body exoskeleton that alleviates the burden of repetitive work. Building on the Company’s trailblazing EksoVest technology, EVO’s innovative design is the next step in the evolution of industrial exoskeletons.Through collaborations with leaders in global manufacturing and construction, Ekso Bionics has accumulated a wealth of in-the-field customer insights that allowed it to reimagine its weight-assist exoskeleton technology. EVO is lighter and more flexible than its predecessor, with an optimized human-machine interface that is cool and comfortable to wear for all-day use, while also maintaining the ruggedness and durability that Ekso is known for. EVO’s novel design also incorporates Ekso’s new patented low profile, multi-link structure, which tracks the natural movement of the body and allows for an unrestricted range of motion, and a device architecture that is compatible with standard safety harnesses used in elevated work. These advancements in design make EVO the ideal solution for a wide range of industrial, manufacturing, food processing, and construction applications.“Through working closely with our customers, we gained tremendous insights and feedback that help us evolve EVO to better meet their needs and provide a programmatic solution to some of their most complicated ergonomic problems,” said Michael Pratt, vice president at Ekso Bionics. “By augmenting human capabilities, EVO was designed to relieve the burden on industrial workers and provide them with a technology solution that improves their quality of life. True to our mission, we are now offering a flexible acquisition model that will lower the capital barrier and allow more industrial workers access to the latest exoskeleton technology.”Shoulder injuries caused by overhead work, repetitive tasks, and overexertion is the leading cause of lost work days due to workplace injuries. Ekso Bionics is striving to alleviate the burden on skilled workers, drastically reducing the number of workplace injuries and cutting down on worker fatigue.EVO is a passive, spring-loaded assistive upper-body exoskeleton that aids workers with overhead work. It is designed to reduce fatigue and shoulder and back muscle strain, with the goal of eliminating work-related injuries to the neck, shoulder, and back. EVO offers 5-15 pounds of lift assistance in each arm to elevate and alleviate the day-to-day strain on workers across all industries. For more information on EVO, please visit our website at www.eksobionics.com and request a virtual demonstration.About Ekso Bionics®  Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com or follow @EksoBionics on Twitter.Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding he potential benefits, performance and effectiveness of the Company’s products and systems, including EVO. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing or maintain operating revenues (including as a result of the COVID-19 pandemic) to fund the Company’s operations and necessary to develop or enhance the Company’s technology, the significant length of time and resources associated with the development of the Company’s products, the Company’s failure to achieve broad market acceptance of the Company’s products, the failure of the Company’s sales and marketing efforts or of partners to market the Company’s products effectively, adverse results in future clinical studies of the Company’s medical device products, the failure to obtain or maintain patent protection for the Company’s technology, the failure of the Company to obtain or maintain regulatory approval to market the Company’s medical devices, disruptions in the Company’s supply chain due to the outbreak of the COVID-19 virus and other delays that may result from the COVID-19 pandemic, the Company’s lack of product diversification, existing or increased competition, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the U.S. Securities and Exchange Commission. To learn more about Ekso Bionics please visit the Company’s website at www.eksobionics.com or follow @EksoBionics on Twitter. The Company does not undertake to update these forward-looking statements.Media Contact: Carrie Yamond Mas 917-371-2320 cmas@eksobionics.comInvestor Contact: David Carey 212-867-1768 investors@eksobionics.comPhotos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/a83bd57f-ea8f-4b37-a4bd-a530fe891de8 https://www.globenewswire.com/NewsRoom/AttachmentNg/83960b98-aea4-432f-a3c6-0c79fd0f5831A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/abddabd9-a97c-4cf8-9e4e-bacc65fb622b. The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress. A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/92c2c7b9-dac1-4034-b7a0-1f091cdaff19